In this issue:
– Standardised definitions for evaluating ADHF therapies
– Optimising evidence-based HF medications after an acute HF admission
– Clinical features of HFnEF
– Aspirin and hemocompatibility events with an LVAD in advanced HF
– Maternal and pregnancy outcomes following HT
– A novel diagnostic HFRS using a minimally invasive sc ICM
– Dapagliflozin (Forxiga) listed on PBS for chronic heart failure
– Expanded access to empagliflozin (Jardiance)
– Correction to focused update of ESC HF guidelines
– Updated guidelines for diagnosing and managing AF
– Recognising clinical trajectories using machine learning in hospitalised patients with HF
– COVID-19 resources
– Conferences, workshops and CPD
Download the Heart Failure Practice Review Issue 2 (pdf) here.